T1	Participants 61 98	acute myelogenous leukemia in relapse
T2	Participants 130 235	Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy
T3	Participants 505 584	three of 25 patients given high-dose cytarabine and three of 23 given amsacrine
